Published in Invest New Drugs on March 30, 2011
Drug discovery targeting cell division proteins, microtubules and FtsZ. Bioorg Med Chem (2014) 0.86
Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat (2015) 0.75
Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Pharmacogenomics J (2016) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol (1989) 7.47
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res (2005) 4.38
The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci (2006) 1.63
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem (1996) 1.52
Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads. Acc Chem Res (2007) 1.36
Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem (2008) 1.29
Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem (2007) 1.26
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res (2005) 1.20
Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. J Med Chem (1997) 1.09
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res (2002) 1.09
Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol (2006) 1.09
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs (2010) 1.05
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther (2003) 0.99
VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett (2005) 0.96
Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J Natl Cancer Inst (2001) 0.94
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract (2010) 0.91
Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model (2009) 0.88
Relevant animal model of human lymphoblastic leukaemia/lymphoma--spontaneous T-cell lymphomas in an inbred Sprague-Dawley rat strain (SD/Cub). Folia Biol (Praha) (2002) 0.87
Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells. Anticancer Res (2005) 0.86
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res (2001) 0.86
Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.85
Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells. Anticancer Res (2009) 0.85
Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells (2005) 0.85
Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs (2009) 0.84
Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch Toxicol (2000) 0.83
Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res (2002) 0.82
Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica (2006) 0.82
Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics (2008) 0.81
Fluoride as a pro-inflammatory factor and inhibitor of ATP bioavailability in differentiated human THP1 monocytic cells. Toxicol Lett (2010) 0.80
Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats. Eur J Pharm Sci (2006) 0.78
Antitumor effects of IDN5109 on head and neck squamous cell carcinoma. Oncol Rep (2006) 0.77
The effects of vinblastine on endothelial cells. Endothelium (2008) 0.77
Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer (2010) 0.77
Anticancer effect of PMEDAP--monitoring of apoptosis. Anticancer Res (2000) 0.75
Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem (2005) 1.77
Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc (2008) 1.56
Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. J Med Chem (2006) 1.30
Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem (2008) 1.29
Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. J Med Chem (2010) 1.29
Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med (2002) 1.25
Use of the tubulin bound paclitaxel conformation for structure-based rational drug design. Chem Biol (2005) 1.24
Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem (2010) 1.19
FtsZ: a novel target for tuberculosis drug discovery. Curr Top Med Chem (2007) 1.18
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther (2003) 1.18
Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Med Chem (2010) 1.14
Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus. Biochemistry (2008) 1.13
Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett (2005) 1.12
A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther (2005) 1.07
Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One (2012) 1.07
Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos (2004) 1.05
Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery. Tuberculosis (Edinb) (2008) 1.04
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol (2004) 1.03
Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res (2004) 1.02
New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer (2010) 1.01
The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics (2013) 1.01
Therapeutic potential of FtsZ inhibition: a patent perspective. Expert Opin Ther Pat (2011) 1.00
Efficient syntheses of crispine A and harmicine by RH-catalyzed cyclohydrocarbonylation. Org Lett (2009) 0.98
Recent advances in the study of the bioactive conformation of taxol. ChemMedChem (2009) 0.94
Synthesis of novel C2-C3'N-linked macrocyclic taxoids by means of highly regioselective Heck macrocyclization. Org Lett (2003) 0.94
Antibody-cytotoxic agent conjugates for cancer therapy. Expert Opin Drug Deliv (2005) 0.93
Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer (2011) 0.93
On the mechanism of gating charge movement of ClC-5, a human Cl(-)/H(+) antiporter. Biophys J (2012) 0.92
Different antioxidant effects of polyphenols on lipid peroxidation and hydroxyl radicals in the NADPH-, Fe-ascorbate- and Fe-microsomal systems. Biochem Pharmacol (2003) 0.91
New biphenol-based, fine-tunable monodentate phosphoramidite ligands for catalytic asymmetric transformations. Proc Natl Acad Sci U S A (2004) 0.90
Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents. J Med Chem (2012) 0.89
SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents. J Med Chem (2013) 0.89
Synthesis of new chiral monodentate phosphite ligands and their use in catalytic asymmetric hydrogenation. Org Lett (2003) 0.89
The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos (2007) 0.88
Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet (2004) 0.88
New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals. Anticancer Drugs (2011) 0.87
Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg Med Chem (2013) 0.87
Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells. Anticancer Res (2005) 0.86
Detection of photosynthetic herbicides: algal growth inhibition test vs. electrochemical photosystem II biosensor. Ecotoxicol Environ Saf (2010) 0.86
Targeted and armed oncolytic adenovirus via chemoselective modification. Bioorg Med Chem Lett (2011) 0.86
Design, synthesis, and biological evaluation of novel C14-C3'BzN-linked macrocyclic taxoids. J Org Chem (2008) 0.86
Synthesis and Biological Evaluation of Novel 3'-Difluorovinyl Taxoids. J Fluor Chem (2012) 0.86
Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.85
Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells. Anticancer Res (2009) 0.85
Syntheses and Structure-Activity Relationships of Novel 3'-Difluoromethyl and 3'-Trifluoromethyl-Taxoids. J Fluor Chem (2008) 0.85
Advances in the chemistry of β-lactam and its medicinal applications. Tetrahedron (2012) 0.85
Importance of ABCC1 for cancer therapy and prognosis. Drug Metab Rev (2014) 0.85
Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Chem Biol (2002) 0.84
Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24. PLoS One (2013) 0.84
Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton. Bioorg Med Chem Lett (2004) 0.84
RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res (2008) 0.84
Inhibitory effect of unsaturated fatty acids on saturated fatty acid-induced apoptosis in human pancreatic β-cells: activation of caspases and ER stress induction. Cell Physiol Biochem (2011) 0.84
Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs (2009) 0.84
New and efficient synthesis of azabicyclo[4.4.0]alkane amino acids by Rh-catalyzed cyclohydrocarbonylation. Org Lett (2002) 0.83
Molecular determinants of Pb2+ interaction with NMDA receptor channels. Neurochem Int (2007) 0.83
Highly enantioselective copper-catalyzed conjugate addition of diethylzinc to nitroalkenes. Org Lett (2004) 0.83
The Arabidopsis central vacuole as an expression system for intracellular transporters: functional characterization of the Cl-/H+ exchanger CLC-7. J Physiol (2012) 0.82
Total synthesis of enantiopure (+)-gamma-lycorane using highly efficient Pd-catalyzed asymmetric allylic alkylation. Org Lett (2006) 0.82
Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics (2008) 0.81
Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr Med Chem Anticancer Agents (2003) 0.81
Caspase-2 is involved in cell death induction by taxanes in breast cancer cells. Cancer Cell Int (2013) 0.81
Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin. Bioorg Med Chem Lett (2009) 0.81
Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy. J Med Chem (2014) 0.81
Novel [2 + 2 + 2 + 1] cycloaddition of enediynes catalyzed by rhodium complexes. Org Lett (2004) 0.80
Electronic effects on the regio- and enantioselectivity of the asymmetric aminohydroxylation of O-substituted 4-hydroxy-2-butenoates. Chirality (2002) 0.80
Caspase-2 and JNK activated by saturated fatty acids are not involved in apoptosis induction but modulate ER stress in human pancreatic β-cells. Cell Physiol Biochem (2013) 0.80
SB-RA-2001 inhibits bacterial proliferation by targeting FtsZ assembly. Biochemistry (2014) 0.80
Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.80
Silicon-initiated carbonylative carbotricyclization and [2+2+2+1] cycloaddition of enediynes catalyzed by rhodium complexes. J Am Chem Soc (2005) 0.80
Synthesis of (13) C2 (15) N2 -labeled anti-inflammatory and cytoprotective tricyclic bis(cyanoenone) ([(13) C2 (15) N2 ]-TBE-31) as an internal standard for quantification by stable isotope dilution LC-MS method. J Labelled Comp Radiopharm (2014) 0.79
Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport? Bioorg Med Chem (2006) 0.79
Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br J Pharmacol (2011) 0.79
Application of Rhodium-Catalyzed Cyclohydrocarbonylation to the Syntheses of Enantiopure Homokainoids. Pure Appl Chem (2008) 0.79
Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression. Future Oncol (2013) 0.79
Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis. Clin Chem Lab Med (2012) 0.78
Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies. Bioorg Med Chem Lett (2004) 0.78
Scorpion toxins that block transient currents (I(A)) of rat cerebellum granular cells. Toxicol Lett (2009) 0.78
Multiplex single-tube screening for mutations in the Nijmegen Breakage Syndrome (NBS1) gene in Hodgkin's and non-Hodgkin's lymphoma patients of Slavic origin. Eur J Hum Genet (2003) 0.78
Novel Taxoid-Based Tumor-Targeting Drug Conjugates. Chim Oggi (2009) 0.78
Highly efficient synthesis of azabicyclo[x.y.0]alkane amino acids and congeners by means of Rh-catalyzed cyclohydrocarbonylation. J Org Chem (2007) 0.78
Molecular determinants of multiple effects of nickel on NMDA receptor channels. Neurotox Res (2009) 0.78